Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRO I.V. IN PLASTIC CONTAINER vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Treatment of intra-abdominal infections (peritonitis, intra-abdominal abscess),Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (amebic dysentery and amebic liver abscess),Treatment of skin and skin structure infections (decubitus ulcers, infected wounds),Treatment of gynecologic infections (endometritis, tubo-ovarian abscess),Treatment of central nervous system infections (meningitis, brain abscess),Treatment of septicemia and endocarditis,Off-label: Perioperative prophylaxis for colorectal surgery,Off-label: Treatment of Helicobacter pylori infection (combined with other agents),Off-label: Crohn's disease (perianal fistulas)
Management of mild to moderate pain,Reduction of fever
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Hepatic metabolism via oxidation and glucuronidation, primarily by CYP450 enzymes (CYP2A6, CYP3A4). The major metabolites are hydroxymetronidazole and metronidazole glucuronide.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
<20% bound to plasma proteins
10-25% bound to albumin at therapeutic concentrations.
0.25-0.85 L/kg; indicates wide distribution into tissues including CSF
0.8-1.0 L/kg; suggests distribution into total body water.
100% intravenous
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Hemodialysis: dose after dialysis.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% (e.g., 500 mg every 12 h).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Neonates (GA <34 wk): 7.5 mg/kg every 12 h; (GA ≥34 wk): 7.5 mg/kg every 8 h. Infants/children: 10 mg/kg every 6-8 h. Max 4 g/day.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Monitor for neurotoxicity.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use should be avoided.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
May cause seizures and peripheral neuropathy; discontinue if neurologic symptoms occur.,Use caution in patients with central nervous system disorders.,Blood dyscrasias: Use with caution in patients with history of or current blood dyscrasias.,Hepatic impairment: Dose adjustment may be required.,Carcinogenicity: Avoid prolonged or unnecessary use.,Drug interactions: Potentiation of anticoagulant effect of warfarin; disulfiram-like reaction with alcohol.,Prolonged QT interval: Use with caution with QT-prolonging agents.,Superinfection: May cause overgrowth of Clostridioides difficile.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (relative contraindication; use only if clearly needed),Breastfeeding (manufacturer recommends discontinuation of nursing or drug, but AAP considers compatible),Use with disulfiram (within 2 weeks of disulfiram administration),Use with alcohol or propylene glycol-containing products (due to disulfiram-like reaction)
Hypersensitivity to acetaminophen or any component of the formulation
Avoid alcohol and any foods or beverages containing alcohol (e.g., beer, wine, liquor, some vinegars, certain desserts) for 48 hours after last dose. No other significant food interactions.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies suggest a possible small risk of cleft palate. The CDC and FDA consider it contraindicated in the first trimester unless clearly needed. In the second and third trimesters, it is generally considered safe, but caution is advised near term due to potential neonatal accumulation.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Metronidazole is excreted into breast milk with milk-to-plasma ratio of approximately 0.6-1.0. Peak milk concentrations occur 2-4 hours after dose. The American Academy of Pediatrics considers it compatible with breastfeeding, but some sources advise discarding milk for 12-24 hours after a single high dose (2 g) to reduce infant exposure. For standard dosing, benefits likely outweigh risks.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic clearance) may reduce serum concentrations of metronidazole, but the clinical significance is unclear. No dose adjustment is routinely recommended; however, for serious infections, therapeutic drug monitoring may be considered. Standard dosing (e.g., 500 mg IV every 8 hours) is typically used.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Metronidazole IV exhibits excellent bioavailability; oral and IV dosing are equivalent. Avoid ethanol-containing medications or diet due to disulfiram-like reaction. Monitor for peripheral neuropathy with prolonged use. Adjust dose in severe hepatic impairment (Child-Pugh C).
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Do not consume alcohol or products containing propylene glycol during treatment and for at least 48 hours after completion.,Report any numbness, tingling, or burning in hands or feet immediately.,Complete the full course as prescribed even if symptoms improve.,May cause metallic or bitter taste; this is temporary and harmless.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRO I.V. IN PLASTIC CONTAINER vs INJECTAPAP, answered by our medical review team.
METRO I.V. IN PLASTIC CONTAINER is a Antibiotic (Nitroimidazole) that works by Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRO I.V. IN PLASTIC CONTAINER and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRO I.V. IN PLASTIC CONTAINER is: IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRO I.V. IN PLASTIC CONTAINER and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRO I.V. IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies sugges. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.